16,054 reports of this reaction
3.6% of all ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, manufactured by Kenvue Brands LLC. There are 16,054 FDA adverse event reports linking ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE to FATIGUE. This represents approximately 3.6% of all 444,449 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 16,054 FDA reports for ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.6% of all adverse event reports for ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience fatigue while taking ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.